Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.

Meaghan Dendy Case,Anish Ghodadra,Paula M. Novelli,Vincent Wu,Suvranu Ganguli,Moritz Wildgruber,Michael Köhler,Charles Robinson,Charles Y. Kim,David S. Wang,Daniel Y. Sze,Kenneth J. Kolbeck,Lori Russell,Johannes M. Ludwig,Johannes Uhlig,Kevin Kim

Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment.

2020

Meaghan Dendy Case
Anish Ghodadra
Paula M. Novelli
Vincent Wu
Suvranu Ganguli
Moritz Wildgruber
Michael Köhler
Charles Robinson
Charles Y. Kim
David S. Wang
Daniel Y. Sze
Kenneth J. Kolbeck
Lori Russell
Johannes M. Ludwig
Johannes Uhlig
Kevin Kim

e16119Background: Assessment of the clinical outcomes and prognostic value of genomic mutations in colorectal liver metastases treated with Y90 radioembolization. Methods: Multi-institution retrosp...

Keywords:

multicenter study
Oncology
in patient
Pathology
genomic biomarkers
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations